Eagle Pharmaceuticals (EGRX) Gets a Buy Rating from RBC Capital

By Carrie Williams

RBC Capital analyst Randall Stanicky maintained a Buy rating on Eagle Pharmaceuticals (EGRXResearch Report) today and set a price target of $59.00. The company’s shares closed last Monday at $40.94.

According to TipRanks.com, Stanicky is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -21.5% and a 18.4% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Osmotica Pharmaceuticals, and Pacira Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eagle Pharmaceuticals with a $50.67 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $64.94 and a one-year low of $33.80. Currently, Eagle Pharmaceuticals has an average volume of 176.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.